Pharmafile Logo
Pharmafocus logo
Advanced Search

NICE

Showing 15 posts of 853 posts found.

astrazeneca_sign_sky

NICE recommendation for AstraZeneca’s Calquence in chronic lymphocytic leukaemia populations

December 8, 2020
Manufacturing and Production, Sales and Marketing AstraZeneca, NHS, NICE, UK, leukaemia

The National Institute for Health and Care Excellence (NICE) has recommended that AstraZeneca’s Calquence (acalabrutinib) be used on the NHS in …

News
lilly_building_with_american_flag_web

NICE recommends Lilly’s Emgality for chronic and episodic migraine

November 18, 2020
Research and Development, Sales and Marketing Eli Lilly, NHS, NICE, UK

Eli Lilly’s Emgality (galcanezumab) is set to become an approved option for the prevention of episodic and chronic migraine on …

News

NICE recommends Sanofi’s Cablivi for ultra-rare acute thrombotic thrombocytopenic purpura

November 12, 2020
Sales and Marketing NHS, NICE, Sanofi, pharma

Sanofi’s Cablivi (caplacizumab) has received recommendation from NICE for routine NHS use in England and Wales for the treatment of …

News
nice_reception_2

NICE recommends venetoclax combo, a non-chemo option for untreated chronic lymphocytic leukaemia

November 10, 2020
Manufacturing and Production, Sales and Marketing AbbVie, NHS, NICE, UK, leukaemia, venetoclax

NICE has recommended venetoclax in combination with obinutuzumab under final draft guidance for the first-line treatment of untreated chronic lymphocytic …

News

NICE shoots down Bristol-Myers Squibb immunotherapy Opdivo for post-surgery skin cancer

November 5, 2020
Sales and Marketing BMS, Cancer, NHS, NICE, opdivo

NICE has rejected the routine use of Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab) on the NHS in England and Wales for …

News
nice_new_london_office_internal_3_web

NICE recommends Novo’s liraglutide for management of obesity and non-diabetic hyperglycaemia

October 30, 2020
Medical Communications, Sales and Marketing NICE, Novo Nordisk, liraglutide

Novo Nordisk’s pre-filled injection Saxenda (liraglutide) has received the backing of drug watchdog NICE, meaning it will now be made …

News
nice_new_london_office_internal_3_web

NICE approves Sanofi’s Sarclisa combo for relapsed/refractory multiple myeloma

October 16, 2020
Medical Communications, Sales and Marketing NICE, Sanofi, Sarclisa, multiple myeloma

Sanofi’s Sarclisa (isatuximab) has secured a recommendation from NICE for routine use on the NHS in England and Wales as …

News
nice_new_london_office_internal_3_web

NICE gives go-ahead for Sandoz’s Rizmoic to treat opioid-induced constipation

September 30, 2020
Research and Development, Sales and Marketing NHS, NICE, Rizmoic, Sandoz, UK

The National Institute for Health and Care Excellence (NICE) has recommended Sandoz’s Rizmoic (naldemedine) for the treatment of opioid-induced constipation …

News

Opdivo scores NICE recommendation in two non-small cell lung cancer indications

September 17, 2020
Sales and Marketing NICE, lung cancer, opdivo

NICE has announced its recommendation of Bristol-Myers Squibb’s blockbuster immunotherapy drug Opdivo (nivolumab) for the treatment of two non-small cell …

News
astrazeneca_sign_sky

NICE U-turns to approve AstraZeneca’s Tagrisso in two new lung cancer indications

September 11, 2020
Medical Communications, Sales and Marketing AstraZeneca, NICE, Tagrisso

NICE has announced the recommendation of AstraZeneca’s Tagrisso (osimertinib) for routine use on the NHS in England and Wales in …

News

NICE opts to reject Celgene’s Revlimid for newly diagnosed multiple myeloma after an autologous stem cell transplant

September 11, 2020
Medical Communications, Sales and Marketing Celgene, NICE, Revlimid

It has emerged that NICE has opted to reject Celgene’s Revlimid (lenalidomide) for the maintenance of newly diagnosed multiple myeloma …

News
nice_new_london_office_internal_3_web

NICE rejects mycosis fungoides-type cutaneous T-cell lymphoma therapy over data concerns

August 5, 2020
Research and Development, Sales and Marketing Ledaga, NICE, lymphoma

NICE has announced its rejection of Ledaga (chlormethine gel), a topical therapy for the treatment of mycosis fungoides-type cutaneous T-cell …

News
nice_reception

Bavencio+Inylta combo approved or Cancer Drugs Fund in advanced renal cell carcinoma

July 31, 2020
Medical Communications, Sales and Marketing Merck, NICE, Pfizer, pharma

NICE has revealed that a combination of Merck KGaA’s Bavencio (avelumab) and Pfizer’s Inlyta (axitinib) will be made available as …

News

NICE shoots down Kyowa Kirin’s Poteligeo for NHS treatment of mycosis fungoides or Sézary syndrome

July 30, 2020
Sales and Marketing Kyowa Kirin, NICE, pharma

NICE has issued draft guidance that has shot down Kyowa Kirin’s therapy Poteligeo (mogamulizumab) for use on the NHS in …

News

Gilteritinib becomes first NICE-approved oral therapy for relapsed or refractory acute myeloid leukaemia

July 16, 2020
Sales and Marketing Atellas, NICE, UK, acute myeloid leukaemia, gilteritinib

NICE has revealed its recommendation of Astellas’ gilteritinib for routine use as a monotherapy on the NHS in England and …

News

Latest content

GSK shares data from global shingles survey

December 1, 2023

AbbVie to acquire ImmunoGen for approximately $10.1bn

December 1, 2023

FDA accepts NDA for Karuna’s schizophrenia treatment

November 30, 2023

Vivos Therapeutics gains FDA 510(k) clearance for sleep apnea treatment device

November 30, 2023

Tolremo doses first patient in phase 1 trial for drug to combat transcriptional cancer drug resistance

November 29, 2023